MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones
Portfolio Pulse from Benzinga Newsdesk
MaxCyte has signed a license agreement with Legend Biotech, granting Legend a non-exclusive worldwide license to use MaxCyte's Flow Electroporation and ExPERT platform. MaxCyte will be eligible for fees and milestones.
May 22, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech has obtained a non-exclusive worldwide license to use MaxCyte's Flow Electroporation and ExPERT platform, which could enhance its technological capabilities.
The license agreement with MaxCyte could enhance Legend Biotech's technological capabilities, potentially leading to advancements in their biotech solutions and positively impacting their stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
MaxCyte has entered into a license agreement with Legend Biotech, allowing Legend to use its Flow Electroporation and ExPERT platform. MaxCyte will receive fees and milestone payments.
The agreement with Legend Biotech is likely to generate additional revenue streams for MaxCyte through fees and milestone payments, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100